Annexin V positivity of CLL cells following incubation with PAS
| Patient no. . | PAS concentration (μM) . | |||
|---|---|---|---|---|
| 5 . | 10 . | 15 . | 20 . | |
| AS8 | 0 | 0 | 0 | 18.2 |
| AS27 | 2.5 | 4.9 | 20.7 | 55.0 |
| AS30 | 0 | ND | 15.3 | 43.1 |
| AS31 | 0.2 | 6.4 | 69.8 | 75.2 |
| AS32 | 0 | 10.5 | 54.8 | 59.7 |
| Patient no. . | PAS concentration (μM) . | |||
|---|---|---|---|---|
| 5 . | 10 . | 15 . | 20 . | |
| AS8 | 0 | 0 | 0 | 18.2 |
| AS27 | 2.5 | 4.9 | 20.7 | 55.0 |
| AS30 | 0 | ND | 15.3 | 43.1 |
| AS31 | 0.2 | 6.4 | 69.8 | 75.2 |
| AS32 | 0 | 10.5 | 54.8 | 59.7 |
CLL cells from 5 patients were incubated with increasing concentrations of PAS for 24 hours. The percentage of annexin V/propidium iodide–positive cells was determined by FACScan analysis. The PAS-specific increase in the percentage of annexin V–positive cells was computed using an established equation.36 ND indicates not determined.